« Return to News | R&D Trends

Xention, Servier collaborate for atrial fibrillation treatment

Wednesday, October 2, 2013 12:59 PM

Xention, a Cambridge-based biopharmaceutical company specializing in discovery and development of ion channel-modulating drugs for atrial fibrillation (AF), and Servier, an independent French pharmaceutical company, have entered  a multi-year agreement for  development and commercialization of XEN-D0103, a selective Kv1.5 modulator discovered and developed by Xention for the treatment of AF.

Servier has received an option to acquire intellectual property rights and to further develop and commercialize XEN-D0103 in all territories except the U.S. and Japan.  All rights in the U.S. and Japan will be retained by Xention.

The clinical development of XEN-D0103 will include two phase II clinical studies aimed at demonstrating the efficacy of XEN-D0103 in reducing AF burden in paroxysmal AF. In addition to an upfront fee, Servier will pay an option fee and milestones totalling $162.5 million. Servier will be responsible for further clinical development and commercialization of XEN-D0103 within its territories.

XEN-D0103 is a selective blocker of Kv1.5, a potassium channel expressed in the atria, which has been shown to be safe and well-tolerated in phase I clinical development.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.